EOLS241115P20000
- 4.10
- 0.000.00%
Evolus Newsroom
Express News | Evolus Rewards™ Patient Loyalty Program Surpasses 1 Million Enrolled Consumers
Evolus Rewards Patient Loyalty Program Surpasses 1 Million Enrolled Consumers
Evolus to Report Third Quarter Financial Results on November 6, 2024
While Shareholders of Evolus (NASDAQ:EOLS) Are in the Black Over 1 Year, Those Who Bought a Week Ago Aren't so Fortunate
Evolus' (NASDAQ:EOLS) Investors Will Be Pleased With Their Solid 119% Return Over the Last Three Years
Evolus Inc (EOLS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements
H.C. Wainwright Maintains Evolus(EOLS.US) With Buy Rating, Maintains Target Price $27
Evolus Poised for Robust Growth With Market Share Gains and Innovative 'Cold Technology' Fillers
Evolus Down Nearly 6%, on Pace for Largest Percent Decrease Since August 2023 -- Data Talk
Evolus Is Maintained at Overweight by Barclays
Analyst Scoreboard: 4 Ratings For Evolus
Stifel Maintains Evolus(EOLS.US) With Buy Rating, Maintains Target Price $25
Stifel analyst Annabel Samimy maintains $Evolus(EOLS.US)$ with a buy rating, and maintains the target price at $25.According to TipRanks data, the analyst has a success rate of 45.1% and a total
Stifel Nicolaus Reaffirms Their Buy Rating on Evolus (EOLS)
When Will Evolus, Inc. (NASDAQ:EOLS) Breakeven?
Needham Maintains Evolus(EOLS.US) With Buy Rating, Maintains Target Price $22
Needham analyst Serge Belanger maintains $Evolus(EOLS.US)$ with a buy rating, and maintains the target price at $22.According to TipRanks data, the analyst has a success rate of 41.6% and a total
Evolus Buy Rating Justified by Strong Market Positioning and Growth Projections
Express News | Evolus Inc : Mizuho Raises Target Price to $25 From $23
Barclays Maintains Evolus(EOLS.US) With Buy Rating, Raises Target Price to $20
Barclays analyst Balaji Prasad maintains $Evolus(EOLS.US)$ with a buy rating, and adjusts the target price from $16 to $20.According to TipRanks data, the analyst has a success rate of 47.2% and a
Mizuho Securities Maintains Evolus(EOLS.US) With Buy Rating, Maintains Target Price $23
Mizuho Securities analyst Uy Ear maintains $Evolus(EOLS.US)$ with a buy rating, and maintains the target price at $23.According to TipRanks data, the analyst has a success rate of 40.4% and a total
Cantor Fitzgerald Reiterates Overweight on Evolus